Latest news

• India turns down patent on Gilead's Sovaldi

  Last year, Sovaldi's Indian intellectual property (IP) also faced a "pre-grant" objection from domestic pharma company Natco as well as the New York-based Initiative for Medicines, Access &Knowledge ... The Indian ruling suggests other drugmakers like

• BMS says it defends Sprycel patent in India

  BDR had been trying to secure a compulsory license to overturn BMS' 2010 Indian patent on Sprycel on the grounds of public need, a strategy which allowed Natco Pharma to start ... Towards the end of last year court documents suggested Natco was no longer

• Bayer fails to overturn Nexavar compulsory licence in India

  Natco Pharma allowed to sell cut-price version of cancer drug. Bayer's first attempt at overturning a compulsory license in India for its cancer drug Nexavar was knocked back yesterday ... The Intellectual Property Appellate Board (IPAB) upheld the

• India could hit Roche and BMS with compulsory licences

  The first compulsory licence in India was introduced last year for Bayer's liver cancer drug Nexevar (sorefinib), allowing Natco Pharma to sell a copy of the treatment that was 95 ... It is a very good move and will not just benefit Indians but possibly